StockData
Belite Bio, Inc logo

Belite Bio, Inc (BLTE) stock

BLTENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026Score 5/30
$164.35−5.61 (-3.30%)

Close on Nov 13, 2026Market cap $6.47BP/E –Yield –

Earnings

Belite Bio's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q4 FY2024
–
EPS, Q4 FY2024
-$0.32
-$0.25 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Belite Bio's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2024ended Dec 31, 2024Mar 17, 2025before the open––-$0.32Release
Q4 FY2023ended Dec 31, 2023Mar 12, 2024after the close––-$0.25Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Belite Bio has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Belite Bio puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Belite Bio filed with the SEC as exhibits to Form 8-K or 6-K

  1. Unaudited Third Quarter 2026 Financial Results and Provides a Corporate Update
    6-K
  2. Uplisting to the Nasdaq Global Select Market
    6-K
  3. Belite Bio Announces Submission of New Drug
    6-K
  4. Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update
    6-K
  5. U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application
    6-K
  6. Bio Completes Rolling Submission of New Drug Application to
    6-K
  7. Belite Bio Reports Unaudited First Quarter
    6-K
  8. Belite Bio Initiates Rolling Submission of New
    6-K
  9. Availability of Annual Report on Form 20-F
    6-K
  10. Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full
    6-K
  11. Belite Bio Completes Enrollment in the DRAGON
    6-K
  12. Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares
    6-K
  13. (Amounts in thousands of US Dollars, except
    6-K
  14. Discussion and Analysis of Financial Condition and Results of Operations
    6-K
  15. Belite Bio Announces Proposed Underwritten Public
    6-K

See a number that looks wrong?